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Abstract 
Background: Beta interferon is one of the important drugs for multiple sclerosis. Its common side effects are 
flu-like symptoms caused by drug injection. The purpose of this study was to evaluate the possibility of 
predicting the response rate of this drug based on the flu-like drug reaction. 
Materials and Methods: This case-control study performed in Loghman Hakim hospital in Tehran in 2017 and 
110 patients with multiple sclerosis under beta interferon treatment studied. Patients were divided into two 
groups with and without flu-like drug reaction. A neurology resident according to the patient’s history and 
patient records filled in the questionnaires. The results of the two groups were compared by SPSS 16 software. 
Results: A total of 110 patients including 31 patients with flu-like drug reaction and 79 non-complicated 
patients were evaluated. These patients included 32 males and 78 females with an average age of 35.55 
years. The mean duration of beta interferon use was 4.33 years in the case group and 4.34 years in the control 
group. Finally, a significant correlation between the flu-like drug reaction and the optimal response in the 
first year treatment was found (p=0.026). In addition, cause of drug discontinuation had significant 
correlation with presence of flu like drug reaction (p=0.028). There was no significant correlation between 
the disease annual attacks rate and flu like drug reaction. 
Conclusion: Flu-like drug reaction is a common complication of interferon beta drugs, which has a therapeutic 
difference in patients with and without this drug reaction. 
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Introduction 
Multiple Sclerosis (MS) is a chronic inflammatory 
demyelinating disease of the central nervous system 
(CNS) of unknown cause. The course is extremely 
variable, but most patients initially experience 
relapses with complete or near-complete recovery 
interspersed with periods of clinical remission. 
Although a minority of patients has only minimal 
symptoms, many become disabled in time because of 
incomplete recovery from relapses or conversion to a 
progressive form of the disease. MS affects 
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approximately 400,000 people in the United States 
and 2.5 million worldwide. It is a leading cause of 
non-traumatic disability in young adults. The disease 
typically begins between the ages of 20 and 40 
years
1
. The incidence of MS is two or three times 
higher in women than in men
2
. 
According to the latest statistics of the Iranian 
multiple sclerosis society, the prevalence of multiple 
sclerosis in Iran is about 70,000. In the province of 
Tehran (capital city of Iran) in 2008, the disease was 
50 per 100,000 people, and in 2015, it reached 115 
per 100,000 people
3
. The point is that the disease 
affects young people and the active workforce of the 
community.  
Multiple sclerosis treatments generally include 
treatment for acute attacks, symptomatic treatments, 
and modulators of disease
3
. Beta interferon is one of 
first step disease modifying drugs that reduce clinical 
attacks and new T2 lesion in MRI 
4
. In addition, this 
drug reduce the speed of progression of disease in 
relapsing remitting type of disease
5
. Side effects from 
interferon beta included skin reactions, flu-like 
symptoms, fatigue, leukopenia, new or worsened 
depression, and new or worsened headache
6
. Flu like 
syndrome is one of the known side effects of this 
drug that include fever, muscle aches, chills and 
fatigue
7
. Beta interferon is used in two types 1A and 
B. One form of beta interferon 1A is used weekly 
intramuscular (avonex) and another form 3 times a 
week under the skin (Rebif). Beta interferon 1B is 
also used subcutaneously every other day 
(Betaferon)
8
. There are some copied 
biopharmaceuticals drugs of these in Iran. Cinnovex 
and Actovex are for Avonex, Recigen and Actorif for 
Rebif and Ziferon, Actoferon and Extavia for 
Betaferon
9
. In patients with relapsing remitting 
multiple sclerosis, little difference in relapse 
outcomes were found between beta interferon-1a SC 
(Rebif
®
) and beta interferon-1b (Betaseron
®
), while 
beta interferon-1a IM (Avonex
®
) was less effective 
than beta interferon-1a SC (Rebif
®






Several mechanisms have been described for the 
effect of beta interferon, including the regulation of 
the secretion of cytokines and signaling molecules 
(including CD86, CD40 and PD-L2), preventing the 
migration of inflammatory cells to the central 
nervous system and preventing activation and 
proliferation of T_lymphocyte
11
. Like other, multiple 
sclerosis drugs, beta interferon drugs are considered as 
expensive drugs that cost a lot to the health system of 
the country. For example Avonex that is one of the 
cheapest multiple sclerosis drugs had median average 
cost 62394 $ per patient per year in 2013 in the United 
States
12
. The efficacy of each modifying drug in the 
studied population is expressed relative to the control 
population and the efficacy of each drug in each 
patient is not predicChart. According to the latest 
guide provided in the European Journal of Neurology, 
if a severe drug reaction is seen, the drug is displaced 
with a drug of the same level. If the clinical 
progression of disease or the discovery of disease 
progresses in the patient's brain MRI detected then the 
drug changed to higher level drugs
13 
.  
Therefore, in fact, the suitability of a drug in each 
particular patient is evident over time, trying to 
anticipate the effectiveness of the drug in each patient 
as soon as possible after the onset of the drug 
prescription is needed. According to the flu-like drug 
reaction is a common complication of beta-interferon 
drugs and does not occur in all patients, which is 
observed rapidly after the first injection
14,15
, it seems 
that if this drug side effect has relation with these drug 
effectiveness, this prediction could be a great help to 
treat multiple sclerosis patients. The purpose of this 
study was to evaluate the possibility of predicting the 
response rate of this drug based on the flu-like drug 
reaction. 
Methods 
This case-control study was conducted in Loghman 
Hakim hospital in Tehran, capital of Iran in 2017. In 
this study, the dependent variable was a desirable 
therapeutic response. The optimal therapeutic response 
was the absence of multiple sclerosis attacks in one 
year or just a sensory isolation attack. Patients divided 
into two groups, with and without flulike side effects 
of drug. For efficacy of beta interferon, the difference 
between patients who received drug and control group 
based on previous studies was about 30%
16
. According 
to this difference by using MedCalc software, the 
sample size for the case group (having flu-like 
syndrome) was at least 30 and for the control group 
(no flu-like syndrome) was at least 80. In this study, 
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multiple sclerosis patients who have been diagnosed 
with McDonald's criteria and who have been taking 
interferon beta for at least 1 year entered to my study. 
The diagnosis of flu-like syndrome was based on the 
presence of fever, muscle aches, chills and fatigue in 
the patients. These symptoms should be repeated at 
each injection, and occurs within an hour to 24 hours 
after injection, and at least two of these four 
symptoms in the patient are required to diagnose the 
flu-like syndrome. A neurology resident in a face-to-
face interview recorded each patient’s information. 
The questionnaire included demographic data of 
patients, the presence or absence of flu-like 
syndrome, the number and type of multiple sclerosis 
attacks in order to determine the optimal response 
based on the records of the clinic and the patient's 
hospitalization and need for housing during the flu-
like syndrome for each patient. The inclusion criteria 
was patient satisfaction to participate in the study, 
definitive nature of multiple sclerosis based on 
McDonald's criteria and neurologist confirmation 
who is associate professor. Exclusion criteria 
includes patient dissatisfaction for participation in the 
study, the patient was not in type of relapsing-
remitting MS during drug use, unreliability of history 
, The lack of use of interferon at the onset of the 
disease and using concomitant immunosuppressive 
drugs or during the month before the onset of 
interferon beta. After data collection, data was 
analyzed by using SPSS16 software. This research 
project at the Ethics Committee of Shahid Beheshti 
University of Medical Sciences was reviewed and 
approved. The assigned ethics code was 
IR.SBMU.RETECH.REC.1396.233. 
Results 
A total of 110 patients (32 males (29.1%) and 78 
females (70.9%)) with a mean age of 33.55±8.29 
(mean ± SD) who were between 19 to 55 years of age 
were studied finally. The patients consisted of 31 cases 
and 79 patients. The case group included patients who 
had flu like drug reaction as defined by the criteria, 
and the control group did not have this drug 
complication. 
In the case group, the mean age was 32.9 and the mean 
age in control group was 33.8. Of these, nine patients 
had a history of multiple sclerosis in the first-degree 
family. The average duration of disease (from the time 
of diagnosis of disease in the patients) in the case 
group was 5.85±3.26 years, and this mean in the 
control group was 6.08±4.04 years. The mean duration 
of beta interferon use in the case group was 4.33±2.34 
years and this mean in the control group was 
4.34±2.40 years. 
The most commonly used beta interferon was 
Cinnovex in both groups (58.1% in the case group and 
58.2% in the control group). In the second place, in the 
two groups were Recigen (19.4% in the case group 
and 12.7% in the control group) (Chart 1 and 2).  
At the time of visit of these 110 patients, 84 (76.3%) 
patients were Relapsing-remitting (RRMS) type and 
26 (23.6%) patients were secondary progressive 
(SPMS) type. With details, 3 of the 31 patients (9.6%) 
in the case group were SPMS type and in the control 
group 23 of 79 (29.1%) patients were SPMS type and 
the rest of the patients in both group were RRMS 
(Chart 3). 
In the case group, 41.9% of the patients still were 
 
Chart 1: Type of beta interferon in case group. 
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continuing beta interferon, which was 30.4% in the 
control group. The next frequent drug at the time of 
visit for both group was Fingolimod (35.5% in the 
case group and 22.8% in the control group). The use 
of natalizumab, rituximab and Azathoprine in the 
control group was higher in our patients (Chart 4 and 
5). 
In the case group, the majority of patients had to use 
analgesic for each injection to relieve and tolerate flu 
like symptoms. In 30% of them they used two times 
analgesic for tolerate interferon. Mostly, they 
injected interferon before sleep for better tolerance 
and reduce use of analgesic. The most commonly 
used analgesic was acetaminophen (32.3% of 
patients). The use of Ibuprofen and other forms of this 
drug also included 32.4% of patients. Our patients 
mentioned that reducing the severity of flu like 
symptoms during years of injection was low. 
We reviewed the efficacy of interferon in the first year 
of treatment and compared it between two groups. The 
absence of any clinical attack or just one sensory 
attack in the first year was optimal response in the first 
year. Totally 93 patients of 110 patients (84.5%) 
responded favorably. This rate was 96.8% in the case 
group (30 out of 31 patients) and 79.7% in the control 
group (63 out of 79 patients) (Chart 6). 
 
Chart 2: Type of beta interferon in control group. 
 
 
Chart 3: The population of patients studied by type of disease during the visit. 
 
Evaluation of Association between Flu-Like Syndrome Induced by Beta Interferon Drug …                             Ghaferi et al. 
NBM 241 Novelty in Biomedicine 2019, 4, 237-45 
It means the undesirable response was 20.3% in the 
patients who had not flu like the one drug reaction 
compared with undesirable response of 3% in the 
group with flu like drug reaction. In order to compare 
the two groups with respect to that "optimal 
response" is a qualitative variable, the Chi-square test 
was used and 
Because p-value was 0.026 <0.05, there was a 
significant difference between patients who had or 
had not flu like drug reaction for the first year beta 
interferon favorable response. Because the duration 
of drug use was different in patients who studied, 
patients compared with an average annual attack rate. 
In the case group, the average number of annual 
attacks was 0.199 with a range of 0 to 0.66 attacks 
per year, and in the control group, the number of 
attacks was 0.258 per year, with a range of 0 to 0.66 
attacks per year. For a better interpretation, and 
because “annual attack rate” is a quantitative variable, 
the T-test was used which the p-value was 0.293.So 
we did not find significant relation between annual 
attack rate and presence of flu like drug reaction. We 
also compared the cause of discontinuation in the two 
groups. 41.9% of the patients in the case group and 
30.4% of the patients in the control group were 
continuing usage one type of beta interferon drugs 
Beta interferon drugs for 35.5% of patients in the case 
group and 27.8% of the patients in the control group 
changed to one of second-line drugs by their 
neurologist due to clinical attacks or MRI findings. 
15.2% of patients in the control group, but none of the 
patients in the case group discontinued beta interferon 
 
Chart 4: Type of disease modifying drugs in the case group (at visit time). 
 
 
Chart 5: Type of disease modifying drugs in the control group (at visit time). 
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due to secondary progressive type transformation 
(one of the patients in the case group that was in SP 
type at our visit time discontinued beta interferon 
because of its 5 years absence of clinical attack). 
9.7% of patients in the case group and 11.4% of the 
patients in the control group discontinued drugs 
because of 5-years duration of being free of clinical 
attack by their neurologist order. Unfortunately four 
patients who were discontinued beta interferon for this 
reaseon came back to clinic after one or two years with 
 
Chart 6: Desired response rate in the first year after the start of treatment. 
 
 
Chart 7: Comparison of the cause of Interferon beta treatment discontinuation in case and control groups. 
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cord plaques and had paraparesis.Finally drugs for 
6.5% of patients in the case group and 15.2% of the 
patients in the control group had been changed to 
Glatiramer acetate, especially due to pregnancy 
(Chart 7). 
For comparison of two groups in the cause of 
discontinuation beta interferon Chi-square test were 
used (p=0.028). Therefore, there was a significant 
relationship between the flu like drug side effect and 
the cause of discontinuation of beta interferon. 
Discussion 
As noted above, multiple sclerosis is a disease of the 
central nervous system that affects the young 
generation and is a cause of the disability of the 
young and active generation of the population. The 
most common type is relapsing remitting type of 
disease. The purpose of disease modifying drugs is to 
reduce the number of disease attacks and prevent 
changing to progressive type. Beta interferon drug is 
one of the first line disease modifying drugs that due 
to the lower complications of the medications can 
used in the beginning of the disease
13
. The response 
to treatment varies from patient to patient. Our goal 
was to predict the response to interferon treatment 
from the beginning of the treatment based on the 
patient's bedside. One of the common side effects of 
the drug is flu-like symptoms that does not occur in 
all patients
6
, and our question can use this drug side 
effect as a predictor of drug response. In this study, 
110 patients with MS who had been treated with beta 
interferon since the start of the diagnosis were 
studied. A total of 31 patients had flu like drug 
reaction (case group). The mean age was 33.55±8.29 
at the age range of 19 to 55 years old. In the case 
group, the mean age was 32.9 and in control group 
was 33.8. Mean duration of disease in the case group 
(from the time of diagnosis of disease) was 
5.85±3.26 years, and this mean in the control group 
was 6.08±4.04 years.  
Although the duration of disease is about the same, at 
the time of visit, patients in the case group were 9.6% 
of the SPMS type, while this in the control group was 
29.1%. It is suggested that a more complete and 
precise study of this issue should be considered. 
The mean duration of beta interferon used in the case 
group was 4.33±2.34 years and this mean in the 
control group was 4.34±2.40 years. The most common 
used beta interferon in both groups was Cinnovex. The 
difference between two groups was finally found to be 
significantly different in terms of the optimal 
responses in the first year (p=0.026). The author's 
opinion is that this difference is important from this 
point of view, one year after drug beginning the 
patient evaluate routinely. However, in our review, 
there was no significant association with annual attack 
rate and flu like drug reaction (p=0.293). 
We compared the cause of beta interferon 
discontinuation in two groups, which included 5 types 
1. Continuing beta interferon 2. Changed to second 
line drug due to MRI finding or clinical attack. 3. 
Termination of the drug due to converting to 
secondary progressive type 4. Change to GA a first 
line drug due to pregnancy or drug intolerance. 5. five 
years attack free and drug discontinuation (by their 
neurologist order). These were compared in two 
groups with the Chi-square test, which is due to the 
p=0.028. There was a significant relationship between 
the side effects of flu-like drugs and the cause of 
discontinuation of interferon beta. 
The second type (the changing of the drug to the 
second line drugs due to the MRI finding or clinical 
attack) in the control group was lower (27.8 vs 35.5)! 
We believe more rate of converting to secondary 
progressive form of disease in the control group 
should be considered and considering no response to 
second line drugs in SPMS by their neurologist. 
A study exact similar to our study which studied 
prediction of beta interferon efficacy based on flu like 
reaction drug side effect was not found in valid 
sources. Generally, they tried to find laboratory ways 
to predict the efficacy of the drug. Similarly what was 
done in 2006 by Nakatsuji Y et al, in Japan who 
studied 22 multiple sclerosis patient who on Betaferon 
treatment. Results showed an increase in serum level 
of IL-6 in response to IFN-beta administration was 
associated with headache, arthralgia, and relapse rate 
before treatment, and disability score at the initiation 
of the therapy. Significant association of change of 
serum TNF-alpha with age and headache was 
observed. The important finding in this study was that 
patients with a transient increase in IL-6 in response to 
IFN-beta showed a slow disease progression. This 
result suggests that this transient increase in the serum 
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IL-6 predicts favorable response to IFN-beta 
treatment
17
. In 2008, Wiesemann et al, in Germany 
examined 120 MS patients treated with different 
types of interferon beta. They found a significant 
upregulation of IL-10 and IL-5 serum cytokine levels 
during IFN-beta therapy. However, clinical response 
was only associated with IL-10 serum levels 
(p=0.038; positive predictive value 0.95, negative 
predictive value 0.43) but not with IL-5
18
. In the year 
2000 Montalban et al, in Spain studied on 20 
multiple sclerosis patients requiring beta interferon 
treatment based on guideline. In their study, they 
finally demonstrated that IL-6 levels are lower in MS 
patients having at least one C allele at position -174 
of IL-6 gene, which in turn determined a reduced 
probability of beta interferon related Flu like 
syndrome
19
. In 2015, Bertoli et al, in Italy examined 
the genomics related to the production of IL-6 and 
TNF-α in 190 multiple-sclerosis-receiving beta 
interferon patients with different flu-like responses. 
They found that patients carrying at least one copy of 
the C allele at position -174 in the promoter of IL-6 
gene produced lower levels of IL-6 and were less 
prone to develop FLS, which was also less severe. 
On the contrary, the polymorphism of TNF-α had no 
effect on FLS
20
 .   
Our study limitations were low number of patients 
and being retrospective study. They were compared 
based on patients' clinical attack and they used 
different type of beta interferon. We suggest more 
complete prospective study which investigate more 
factors to compare patients such as patients MRI, 
patients EDSS, type of attacks, and more. It is 
suggested, until accurate studies be performed, for 
patients who treated with beta interferon and do not 
have flu like the one drug reaction more closely 
follow up should be done. Changing drug should be 
considered if necessary.The final point is that 
Unfortunately four patients who discontinued beta 
interferon due to 5 years being attack free came back 
to clinic after one or two years with cord plaques and 
had paraparesis so detailed study should be made 
about it and take care for discontinue drug. 
Conclusion 
Based on the research findings indicating the 
relationship between the efficacy of beta interferon 
drugs and their flu like drug reaction in multiple 
sclerosis patients this drug reaction should be 
monitored in these patient and who don’t have flu like 
drug drug reaction  should be considered as patients 
with lower drug response so closer follow up is 
needed. 
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